Cogent Biosciences (NASDAQ: COGT) director schedules option-led stock sale years ahead

Rhea-AI Filing Summary

Cogent Biosciences, Inc. (COGT) director Arlene Morris filed a notice of proposed sale of company common stock under Rule 144. The filing covers up to 45,510 shares of common stock, with an indicated aggregate value of about $1,671,127.20, to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ, with a proposed sale date of August 27, 2026. The shares are to be sold in connection with an exercise of stock options for cash.

Key Figures

Shares proposed to be sold: 45,510 shares of common stock Approximate aggregate market value: $1,671,127.20 Proposed sale date: 08/27/2026 +2 more

5 metrics

Shares proposed to be sold 45,510 shares of common stock Maximum amount covered by the Rule 144 notice for director Arlene Morris

Approximate aggregate market value $1,671,127.20 Value associated with the 45,510 shares of Cogent Biosciences common stock

Proposed sale date 08/27/2026 Date listed for the proposed Rule 144 sale of common stock

Form 144 signature date 05/28/2026 Date associated with the signature of Arlene Morris on the notice

Issuer SEC file number 001-38443 SEC file number for Cogent Biosciences, Inc.

Key Terms

Rule 144, Exercise of Stock Options, Federal Criminal Violations, Common stock

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Exercise of Stock Options financial

"Common | 08/27/2026 | Exercise of Stock Options | Issuer"

Federal Criminal Violations regulatory

"Intentional misstatements or omission of facts constitute Federal Criminal Violations"

Common stock financial

"144: Securities Information Common | Morgan Stanley Smith Barney LLC"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

What did Cogent Biosciences (COGT) disclose in this Form 144?

The filing reports that director Arlene Morris intends to sell up to 45,510 shares of Cogent Biosciences common stock under Rule 144, in connection with an exercise of stock options for cash, through Morgan Stanley Smith Barney LLC on the NASDAQ.

How many Cogent Biosciences (COGT) shares are covered by this Form 144?

The notice covers up to 45,510 shares of Cogent Biosciences common stock proposed to be sold. The filing associates these shares with an exercise of stock options and lists an approximate aggregate value of $1,671,127.20.

What is the approximate value of the Cogent Biosciences (COGT) shares in this planned sale?

The Form 144 lists an approximate aggregate value of $1,671,127.20 for the 45,510 shares of Cogent Biosciences common stock proposed to be sold by director Arlene Morris.

When is the proposed sale date for the Cogent Biosciences (COGT) shares?

The filing states a proposed sale date of August 27, 2026 for the sale of 45,510 shares of Cogent Biosciences common stock under Rule 144, in connection with an exercise of stock options.

How will the Cogent Biosciences (COGT) shares be sold under this Form 144?

The shares are proposed to be sold as common stock on the NASDAQ through Morgan Stanley Smith Barney LLC. The filing describes the transaction as an Exercise of Stock Options with payment in cash and lists the securities as common stock.

Who is the insider involved in this Cogent Biosciences (COGT) Form 144 filing?

The Form 144 identifies Arlene Morris, a director of Cogent Biosciences, Inc., as the person for whose account the 45,510 shares of common stock are to be sold under Rule 144.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/27/2026 - 04:18 PM Accepted by SEC EDGAR 08/27/2026 - 04:17 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001362520
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Cogent Biosciences, Inc.
SEC File Number	001-38443
Address of Issuer	275 Wyman Street 3rd Floor Waltham MASSACHUSETTS 02451
Phone	617-945-5576
Name of Person for Whose Account the Securities are To Be Sold	ARLENE MORRIS
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	45510	1671127.20	173524982	08/27/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/27/2026	Exercise of Stock Options	Issuer			45510	08/27/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	08/27/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/28/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Arlene Morris
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)